283 related articles for article (PubMed ID: 30968175)
1. Psychopathological symptoms associated with synthetic cannabinoid use: a comparison with natural cannabis.
Mensen VT; Vreeker A; Nordgren J; Atkinson A; de la Torre R; Farré M; Ramaekers JG; Brunt TM
Psychopharmacology (Berl); 2019 Sep; 236(9):2677-2685. PubMed ID: 30968175
[TBL] [Abstract][Full Text] [Related]
2. A survey of synthetic cannabinoid consumption by current cannabis users.
Gunderson EW; Haughey HM; Ait-Daoud N; Joshi AS; Hart CL
Subst Abus; 2014; 35(2):184-9. PubMed ID: 24821356
[TBL] [Abstract][Full Text] [Related]
3. Synthetic Cannabinoid Use in a Psychiatric Patient Population: A Pilot Study.
Welter S; Lücke C; Lam AP; Custal C; Moeller S; Sörös P; Thiel CM; Philipsen A; Müller HHO
Eur Addict Res; 2017; 23(4):182-193. PubMed ID: 28848170
[TBL] [Abstract][Full Text] [Related]
4. Characteristics of Synthetic Cannabinoid and Cannabis Users Admitted to a Psychiatric Hospital: A Comparative Study.
Shalit N; Barzilay R; Shoval G; Shlosberg D; Mor N; Zweigenhaft N; Weizman A; Krivoy A
J Clin Psychiatry; 2016 Aug; 77(8):e989-95. PubMed ID: 27379411
[TBL] [Abstract][Full Text] [Related]
5. Do police arrestees substitute legal highs for other drugs?
Wilkins C; Parker K; Prasad J; Jawalkar S
Int J Drug Policy; 2016 May; 31():74-9. PubMed ID: 26948501
[TBL] [Abstract][Full Text] [Related]
6. Assessing the experience of using synthetic cannabinoids by means of interpretative phenomenological analysis.
Kassai S; Pintér JN; Rácz J; Böröndi B; Tóth-Karikó T; Kerekes K; Gyarmathy VA
Harm Reduct J; 2017 Feb; 14(1):9. PubMed ID: 28187774
[TBL] [Abstract][Full Text] [Related]
7. A preliminary evaluation of synthetic cannabinoid use among adolescent cannabis users: Characteristics and treatment outcomes.
Blevins CE; Banes KE; Stephens RS; Walker DD; Roffman RA
Addict Behav; 2016 Dec; 63():114-9. PubMed ID: 27454353
[TBL] [Abstract][Full Text] [Related]
8. Synthetic cannabinoid use among college students.
Mathews EM; Jeffries E; Hsieh C; Jones G; Buckner JD
Addict Behav; 2019 Jun; 93():219-224. PubMed ID: 30772774
[TBL] [Abstract][Full Text] [Related]
9. Mental health symptoms and their relationship to cannabis use in adolescents attending residential treatment.
Albertella L; Norberg MM
J Psychoactive Drugs; 2012; 44(5):381-9. PubMed ID: 23457889
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of cognitive functions in individuals with synthetic cannabinoid use disorder and comparison to individuals with cannabis use disorder.
Cengel HY; Bozkurt M; Evren C; Umut G; Keskinkilic C; Agachanli R
Psychiatry Res; 2018 Apr; 262():46-54. PubMed ID: 29407568
[TBL] [Abstract][Full Text] [Related]
11. Differential physiological and behavioral cues observed in individuals smoking botanical marijuana versus synthetic cannabinoid drugs.
Chase PB; Hawkins J; Mosier J; Jimenez E; Boesen K; Logan BK; Walter FG
Clin Toxicol (Phila); 2016; 54(1):14-9. PubMed ID: 26653952
[TBL] [Abstract][Full Text] [Related]
12. [Comorbidity in 207 cannabis users in a specific outpatient setting].
Guillem E; Arbabzadeh-Bouchez S; Vorspan F; Bellivier F
Encephale; 2015 Jun; 41 Suppl 1():S7-12. PubMed ID: 25123065
[TBL] [Abstract][Full Text] [Related]
13. Psychiatric comorbidity associated with synthetic cannabinoid use compared to cannabis.
Bassir Nia A; Medrano B; Perkel C; Galynker I; Hurd YL
J Psychopharmacol; 2016 Dec; 30(12):1321-1330. PubMed ID: 27462088
[TBL] [Abstract][Full Text] [Related]
14. Synthetic cannabinoid use disorder: an update for general psychiatrists.
Grigg J; Manning V; Arunogiri S; Lubman DI
Australas Psychiatry; 2019 Jun; 27(3):279-283. PubMed ID: 30663326
[TBL] [Abstract][Full Text] [Related]
15. Mental health differences between frequent cannabis users with and without dependence and the general population.
van der Pol P; Liebregts N; de Graaf R; Ten Have M; Korf DJ; van den Brink W; van Laar M
Addiction; 2013 Aug; 108(8):1459-69. PubMed ID: 23530710
[TBL] [Abstract][Full Text] [Related]
16. Risk of emergency medical treatment following consumption of cannabis or synthetic cannabinoids in a large global sample.
Winstock A; Lynskey M; Borschmann R; Waldron J
J Psychopharmacol; 2015 Jun; 29(6):698-703. PubMed ID: 25759401
[TBL] [Abstract][Full Text] [Related]
17. Neuropsychiatric Sequelae in Adolescents With Acute Synthetic Cannabinoid Toxicity.
Anderson SAR; Oprescu AM; Calello DP; Monte A; Dayan PS; Hurd YL; Manini AF;
Pediatrics; 2019 Aug; 144(2):. PubMed ID: 31285395
[TBL] [Abstract][Full Text] [Related]
18. First episode psychosis with and without the use of cannabis and synthetic cannabinoids: Psychopathology, global functioning and suicidal ideation and antipsychotic effectiveness.
Ricci V; Ceci F; Di Carlo F; Di Muzio I; Ciavoni L; Santangelo M; Di Salvo G; Pettorruso M; Martinotti G; Maina G
Psychiatry Res; 2023 Feb; 320():115053. PubMed ID: 36682093
[TBL] [Abstract][Full Text] [Related]
19. "Spice" and "K2" herbal highs: a case series and systematic review of the clinical effects and biopsychosocial implications of synthetic cannabinoid use in humans.
Gunderson EW; Haughey HM; Ait-Daoud N; Joshi AS; Hart CL
Am J Addict; 2012; 21(4):320-6. PubMed ID: 22691010
[TBL] [Abstract][Full Text] [Related]
20. [Sociodemographic profiles, addictive and mental comorbidity in cannabis users in an outpatient specific setting].
Guillem E; Pelissolo A; Vorspan F; Bouchez-Arbabzadeh S; Lépine JP
Encephale; 2009 Jun; 35(3):226-33. PubMed ID: 19540408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
